BTK Inhibitor Orelabrutinib Shows Promising Efficacy in Phase 2 Study of Relapsing-Remitting Multiple Sclerosis

Published Date: 06 Mar 2025

The 80 mg QD dosage, which showed the greatest efficacy in lesion reduction (92.3% at 24 weeks), will be used in phase 3 progressive MS studies.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?

2.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

3.

For patients with prostate cancer, long-term follow-up helps identify treatment side effects.

4.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

5.

Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot